STAT3 Polymorphism Can Predict the Response to Interferon-α Therapy in Patients with Metastatic Renal Cell Carcinoma
- 30 April 2013
- journal article
- research article
- Published by Elsevier BV in European Urology
- Vol. 63 (4), 745-752
- https://doi.org/10.1016/j.eururo.2012.09.052
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology (16390466)
This publication has 29 references indexed in Scilit:
- VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trialsThe Lancet Oncology, 2012
- Copy-number variation and association studies of human diseaseNature Genetics, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironmentNature Reviews Immunology, 2007
- The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cellsThe Journal of Experimental Medicine, 2006
- RECIST revisited: A review of validation studies on tumour assessmentEuropean Journal Of Cancer, 2006
- Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor–β1The Journal of Experimental Medicine, 2006
- Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoproteinThe Journal of Experimental Medicine, 2005
- The STATs of cancer — new molecular targets come of ageNature Reviews Cancer, 2004
- STATs in oncogenesisOncogene, 2000